Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
Trial details
- Registry ID
- NCT04634825
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as MGA271
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerNCT04634825 | MacroGenics | Phase 2 | Terminated | 2022-07-29Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |